Finished Pharmaceutical Products (FPPs) – Page 4

Finished product packaging leakage complaint after packaging material change: manufacturing vs lab root cause mapping and required evidence

The investigation begins with identifying the symptoms or signals that prompted the complaint regarding packaging leakage. Key indicators could include:Click to read the full article.

Finished product assay OOS during deviation triage meeting: how to defend specification setting and outlier handling during inspection

Detecting OOS results during final product assays is typically the first marker that an investigation is warranted. Symptoms may include:Click to read the full article.

Finished product dissolution failure during routine batch release: manufacturing vs lab root cause mapping and required evidence

The first sign of a potential dissolution failure often emerges during routine quality control (QC) testing. Symptoms can vary and may include:Click to read the full article.

Finished product content uniformity OOS during complaint trending review: CAPA plan that inspectors accept (with effectiveness checks and due dates)

OOS results relating to finished product content uniformity may manifest through several symptoms or signals, which can indicate underlying issues in the manufacturing process:Click to read the full article.

Finished product coating non-uniformity during CPV annual product review: how to build a deviation package that passes an inspection deep-dive

Addressing Finished Product Coating Non-Uniformity in CPV Annual Product Reviews In pharmaceutical manufacturing, the integrity and uniformity of product coatings are critical. Deviations observed during annual product reviews, particularly concerning…

Finished product label mix-up deviation during PAI / FDA inspection readiness: manufacturing vs lab root cause mapping and required evidence

Symptoms of a potential finished product label mix-up can manifest in various forms, both on the manufacturing floor and in the quality control lab. Key indicators to monitor include:Click to…

Finished product content uniformity OOS after packaging material change: FDA-compliant investigation flow and batch disposition decision tree

The manifestation of OOS findings regarding content uniformity can arise from various processes in manufacturing, especially during and after a packaging material change. Key symptoms on the production floor or…

Finished product blend uniformity failure during line clearance and changeover: how to build a deviation package that passes an inspection deep-dive

Identifying blend uniformity failure during line clearance hinges on observing specific symptoms or signals that indicate potential issues. These may include:Click to read the full article.

Finished product serialization data mismatch after process parameter adjustment: data integrity review steps for LIMS/EMR/ES and chromatography systems

Identifying symptoms of serialization data mismatch is the first step in addressing potential deviations. Common signals might include:Click to read the full article.

Finished product hardness / friability drift after packaging material change: manufacturing vs lab root cause mapping and required evidence

Identifying the symptoms of finished product hardness or friability drift is the first step in any investigation. Symptoms often manifest as:Click to read the full article.

Finished product particulate matter OOS after method transfer to a new QC lab: stability strategy adjustments and packaging risk mitigation steps

The first step in addressing OOS results for particulate matter is recognizing the symptoms or signals that indicate a potential issue. These can manifest through:Click to read the full article.

Finished product assay OOS during PAI / FDA inspection readiness: updates to master batch record and in-process controls to prevent recurrence

When an OOS result is detected, earlier signals may have been evident yet overlooked. Awareness of these symptoms is key for proactive management:Click to read the full article.